66

Bioinformatics of the Brain

[67] A.-C. Raulin, S. V. Doss, Z. A. Trottier, et al., “Apoe in alzheimer’s

disease: pathophysiology and therapeutic strategies,” Molecular Neu-

rodegeneration, vol. 17, p. 72, 11 2022.

[68] W. J. Strittmatter, A. M. Saunders, D. Schmechel, et al., “Apolipopro-

tein e: high-avidity binding to beta-amyloid and increased frequency of

type 4 allele in late-onset familial alzheimer disease,” Proceedings of the

National Academy of Sciences, vol. 90, pp. 1977–1981, 3 1993.

[69] Y.-T. Lin, J. Seo, F. Gao, et al., “Apoe4 causes widespread molecular

and cellular alterations associated with alzheimer’s disease phenotypes

in human ipsc-derived brain cell types,” Neuron, vol. 98, p. 1294, 6 2018.

[70] K. Meyer, H. M. Feldman, T. Lu, et al., “Rest and neural gene net-

work dysregulation in ipsc models of alzheimer’s disease,” Cell Reports,

vol. 26, pp. 1112–1127.e9, 1 2019.

[71] S. Raman, N. Brookhouser, and D. A. Brafman, “Using human induced

pluripotent stem cells (hipscs) to investigate the mechanisms by which

apolipoprotein e (apoe) contributes to alzheimer’s disease (ad) risk,”

Neurobiology of Disease, vol. 138, p. 104788, 5 2020.

[72] C. Wang, R. Najm, Q. Xu, et al., “Gain of toxic apolipoprotein e4

effects in human ipsc-derived neurons is ameliorated by a small-molecule

structure corrector,” Nature Medicine, vol. 24, pp. 647–657, 5 2018.

[73] E. Doran, D. Keator, E. Head, et al., “Down syndrome, partial trisomy

21, and absence of alzheimer’s disease: The role of app,” Journal of

Alzheimer’s Disease, vol. 56, pp. 459–470, 1 2017.

[74] L. N. Geller and H. Potter, “Chromosome missegregation and trisomy

21 mosaicism in alzheimer’s disease,” Neurobiology of Disease, vol. 6,

pp. 167–179, 6 1999.

[75] H. Potter, A. Granic, and J. Caneus, “Role of trisomy 21 mosaicism in

sporadic and familial alzheimer’s disease,” Current Alzheimer Research,

vol. 13, pp. 7–17, 12 2015.

[76] D. A. Ovchinnikov, O. Korn, I. Virshup, et al., “The impact of app

on alzheimer-like pathogenesis and gene expression in down syndrome

ipsc-derived neurons,” Stem Cell Reports, vol. 11, pp. 32–42, 7 2018.

[77] R. Balez, N. Steiner, M. Engel, et al., “Neuroprotective effects of api-

genin against inflammation, neuronal excitability and apoptosis in an

induced pluripotent stem cell model of alzheimer’s disease,” Scientific

Reports, vol. 6, p. 31450, 8 2016.

[78] N. Yahata, M. Asai, S. Kitaoka, et al., “Anti-aβ drug screening platform

using human ips cell-derived neurons for the treatment of alzheimer’s

disease,” PLoS ONE, vol. 6, p. e25788, 9 2011.